Collaboration and Licensing Agreements (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 31, 2022 USD ($) item	Dec. 31, 2021 USD ($)	Jun. 30, 2018 USD ($) item	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaboration and Licensing Agreements
Deferred revenues		$ 5,538		$ 15,684	$ 5,538
Gilead Collaboration and License Agreement
Collaboration and Licensing Agreements
Number of preclinical research programs | item			2
Upfront payment received			$ 10,000
Program initiation fee			$ 15,000
Payment term (in days)			60 days
Milestone payment received			$ 8,000
Milestone payments included in deferred revenues		4,000			4,000
Percentage of upfront payment included in deferred revenue expected to be recognized in 2023				29.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2024				34.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2025				25.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2026				12.00%
Cost reimbursements for research and development services included in deferred revenues		1,200		$ 0	1,200
Revenue recognized from upfront payment						$ 4,400
Revenue recognized from milestone payments		0		3,700	2,100
Revenue recognized from cost reimbursements for research and development services				5,200	16,300	13,000
Revenue recognized from milestone payments for milestones achieved				5,000		$ 2,200
Contract asset relating to the sublicense payment		300		200	300
Contract liability relating to sublicense payment		300		0	300
Deferred revenues		$ 4,300			$ 4,300
Deferred income				$ 14,300
Roche collaboration agreement
Collaboration and Licensing Agreements
Upfront payment received	$ 25,000
Percentage of upfront payment included in deferred revenue expected to be recognized in 2023				43.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2024				17.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2025				16.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2026				15.00%
Percentage of upfront payment included in deferred revenue expected to be recognized in 2027				9.00%
Revenue recognized from upfront payment				$ 300
Contract asset relating to the sublicense payment				1,500
Contract liability relating to sublicense payment				1,200
Deferred revenues				$ 27,000
Roche collaboration agreement | Minimum
Collaboration and Licensing Agreements
Payment term (in days)	30 days
Roche collaboration agreement | Maximum
Collaboration and Licensing Agreements
Payment term (in days)	60 days
CTA program
Collaboration and Licensing Agreements
Additional payments on exercise of option	$ 15,000
Event based milestone payments	$ 173,000
Number of oncology indications | item	4
Sales based milestone payments	$ 160,000
HB 700 program
Collaboration and Licensing Agreements
Event based milestone payments	$ 335,000
Number of oncology indications | item	4
Sales based milestone payments	$ 250,000
Development Milestones | HBV program
Collaboration and Licensing Agreements
Total milestone amount			140,000
Development Milestones | HIV program
Collaboration and Licensing Agreements
program completion fee			10,000
Development Milestones | HIV program | Maximum
Collaboration and Licensing Agreements
Total milestone amount			172,500
Commercial Milestones | HBV program
Collaboration and Licensing Agreements
Total milestone amount			50,000
Commercial Milestones | HIV program
Collaboration and Licensing Agreements
Total milestone amount			$ 65,000